Closing in on Cancer

We are Merus

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Technology Download Merus' Corporate Presentation
The new face of fighting cancer
The new face of fighting cancer
The new face of fighting cancer
The new face of fighting cancer
Meet our

Management Team

Lex Bakker, Ph.D
SVP & Chief Development Officer
John Crowley, C.P.A.
EVP & Chief Financial Officer
John de Kruif, Ph.D
SVP & Chief Technology Officer
Hui Liu, Ph.D
EVP & Chief Business Officer
Ton Logtenberg, Ph.D
Chief Executive Officer
Peter B. Silverman, J.D.
EVP & General Counsel
L. Andres Sirulnik, M.D. Ph.D
EVP & Chief Medical Officer
Mark Throsby, Ph.D
EVP & Chief Scientific Officer
Meet our

Board of Directors

Lionel Carnot
Member
Mark Iwicki
Chairman
Len Kanavy
Observer
John de Koning, Ph.D
Member
Ton Logtenberg, Ph.D
Chief Executive Officer
Anand Mehra, M.D.
Member
Anne Noordzij
Secretary
Greg Perry, C.P.A.
Member

Investors & Media

Nasdaq

Investor Relations

For more information and the latest news about Merus N.V., please visit our Investor Relations section by clicking the button below.

[This section of the website is under construction. You will be temporarily re-routed to Merus’ old website.] 

Investors & Media
Stock information
Nasdaq : MRUS (Common Stock)
$24.64
Change : 0.69 2.72%
Volume : 55,768
Market Cap : 557.472M
Data as of July 16, 2018 @ 04:00 pm EST
(Data provided by Nasdaq. Maximum 15 minutes delayed)